Sentences with phrase «on lymphoma cells»

Not exact matches

Novartis, for example, spent $ 43 million on a manufacturing facility in Morris Plains, New Jersey, and last week it released results from a lymphoma trial in which cells were frozen and flown to and from patients in 10 countries.

Previous studies of genetic alterations in lymphoma and lung cancer have found that certain genetic mutations — specifically when part of a gene breaks off and gets fused to another — can inappropriately switch on ALK, driving cancer cells to grow and divide.

«There is an unmet need to develop new therapies based on R - CHOP to try to increase the cure rate for diffuse large B - cell lymphoma,» says Patrick Johnston, M.D., Ph.D., a hematologist at Mayo Clinic and lead author.

Classified as either Hodgkin lymphoma or non-Hodgkin lymphoma, depending on which cells are affected, lymphoma accounted for approximately five percent of all new cancers diagnosed in the United States in 2014, according to the National Cancer Institute.

This clinical trial sponsored by Juno Therapeutics is testing JCAR017, which targets the CD19 protein expressed on most B - cell leukemias and lymphomas.

Several years ago, NCI scientists identified the two primary subtypes of DLBCL based on characteristic patterns of gene activity within the lymphoma cells.

Like a free pass, its presence on the surface of lymphoma cells facilitates their migration through the vessel walls between adjacent endothelial cells.

To block this signal, recent clinical studies have focused on inhibiting the activation of the B - cell receptor as a treatment for non-Hodgkin lymphoma patients, but with variable success.

This receptor normally stimulates the growth of B - cells only when it is needed, but in non-Hodgkin lymphoma, the growth signal is constantly on, making B - cells grow uncontrollably.

One of the driving forces behind non-Hodgkin lymphomas is the over-activation of a receptor on the surface of B cells.

Although myeloma is, like leukemias and lymphomas, a cancer involving white blood cells known as lymphocytes, myeloma cells don't traditionally express CD19 on their surface because they arise from the most mature type of lymphocytes — plasma cells.

Scientists know that the lymphoma cells are dependent on a cytokine called IL - 15 which encourages cells to multiply.

Dr Xu showed that for BET inhibitors to successfully kill lymphoma and myeloid leukemia cells the presence of a protein called BIM, which brings on apoptosis, was critical.

Green fluorescent dyes in this microscopic view mark the presence of the glucose transporter, GLUT1, on the surface of lymphoblastoid cells which go on to form the lymphomas caused by Epstein - Barr virus.

The modified T cells contain a protein known as a chimeric antigen receptor (CAR), which is designed to target the CD19 protein found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia and lymphoma.

Beilhack and colleagues found that a slightly modified version of STAR2 has a similar effect on human T reg cells, suggesting that the approach could also prevent GvHD in leukemia and lymphoma patients after bone marrow or hematopoietic stem cell transplants.

BV is an immunotherapy that targets CD30, a protein on the surface of some Hodgkin lymphoma cells, and delivers a potent dose of chemotherapy to destroy the cell.

Based on our data, autologous stem cell transplant should be considered the standard of care for patients with HIV - related lymphomas for the same indications and under the same circumstances that we would use it in patients without HIV infection.»

While the study focused on the T - cells around a lymphoma tumor, this research is pertinent to all types of cancer.

Exon - Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B - Cell / Follicular Grade 3 Lymphoma Patients Treated with Dose - Dense Chemoimmuno - therapy and CNS Prophylaxis.

A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.

Blincyto (blinatumomab) is designed to treat cancers expressing a molecule called CD19 — found on the surface of B cell ALL and also non-Hodgkin's lymphoma.

The first radionuclide - linked monoclonal antibody (ibritumomab tiuxetan, Zevalin) is approved by the FDA (anti-CD20 on B cells) to treat non-Hodgkin lymphoma.

Musso A, Catellani S, Canevali P, Tavella S, Venè R, Boero S, Pierri I, Gobbi M, Kunkl A, Ravetti J - L, Zocchi MR, Poggi A. Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor Vdelta 2T lymphocytes in non-Hodgkin lymphomas.

Heidi Simmons decided to focus on cell therapy for treatment of blood cancers like leukemia, lymphoma and myeloma, where healthy cells are infused into patients to replenish those damaged by cancer.

On the contrary, p21 deficiency delays the onset of radiation - induced T - cell lymphomas, which is in line with the delay in the appearance of spontaneous T - cell lymphomas produced by p21 deficiency in ATM - null mice (32).

Dumler was only the second patient at MD Anderson and the third in the world to receive CAR T cells to treat non-Hodgkin's lymphoma on the multicenter clinical trial.

Small, focused clinical trials are possible for certain B - cell malignancies such as Diffuse Large B - Cell Lymphoma in which patients can be stratified based on NF - kB activation status and / or presence of mutations known to activate NF -cell malignancies such as Diffuse Large B - Cell Lymphoma in which patients can be stratified based on NF - kB activation status and / or presence of mutations known to activate NF -Cell Lymphoma in which patients can be stratified based on NF - kB activation status and / or presence of mutations known to activate NF - kB.

Clinical experiences for the nurse practitioner fellow include rotations on the leukemia, lymphoma, solid tumor, neuro - oncology, late effects, hematology, the inpatient general hematology / oncology unit, hematopoietic stem cell transplant unit, and palliative care.

It is well known that HDAC inhibitors are potent anticancer drugs in hematopoietic malignancies, including lymphoma.19 — 21 The aim of using HDAC inhibitors is to restore normal histone modification patterns through inhibition of various components of the epigenetic machinery.22, 23 In B - cell lymphoma, HDAC inhibitors can rescue deficits in histone acetylation induced by EP300 / CREBBP mutations, 24 rendering tumor cells more sensitive to suberoylanilide hydroxamic acid.25 This can explain why chidamide also has favorable efficacy on PTCL - NOS patients bearing EP300 / CREBBP mutations.

Hodgkin lymphoma is usually treated with chemotherapy, radiation therapy, or a combination of the two, depending on the stage and cell type.

This is in accordance with previous reports that decitabine and 5 - azacytidine produce a marked synergistic effect in combination with suberoylanilide hydroxamic acid and romidepsin in T - lymphoma cell lines by modulating cell cycle arrest and apoptosis.26, 27 As a mechanism of action, KMT2D mutations of B - lymphoma cells promote malignant outgrowth by perturbing methylation of H3K4 that affect the JAK - STAT, Toll - like receptor, or B - cell receptor pathway.28, 29 Here our study indicated that dual treatment with chidamide and decitabine enhanced the interaction of KMT2D with the transcription factor PU.1, thereby inactivating the H3K4me - associated signaling pathway MAPK, which is constitutively activated in T - cell lymphoma.13, 30,31 The transcription factor PU.1 is involved in the development of all hematopoietic lineages32 and regulates lymphoid cell growth and transformation.33 Aberrant PU.1 expression promotes acute myeloid leukemia and is related to the pathogenesis of multiple myeloma via the MAPK pathway.34, 35 On the other hand, PU.1 is also shown to interact with chromatin remodeler and DNA methyltransferease to control hematopoiesis and suppress leukemia.36 Our data thus suggested that the combined action of chidamide and decitabine may interfere with the differentiation and / or viability of PTCL - NOS through a PU.1 - dependent gene expression program.

I was diagnosed with non-Hodgkin's diffuse B - cell lymphoma on Aug. 14, 2015, and since then, I have undergone three rounds of chemotherapy, 22 radiation treatments and an autologous stem cell transplant.

The in vivo anti-tumor activity of dual treatment on T - cell lymphoma was further evaluated in a murine xenograft model in which KMT2D V5486M mutated Jurkat cells subcutaneously injected into nude mice.

Current practice is therefore based on findings from early - phase and retrospective primary CNS lymphoma studies, and extrapolations of survival data among patients with systemic B - cell lymphoma, Dr. Doorduijn said.

The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.

For example, Penn's blood cancer trials employ a CAR targeting the protein CD19, which is found on the surface of B cells, including the cancerous B cells that characterize several types of leukemia and lymphoma.

On February 1st, after my first day at my new job, I was diagnosed with Lymphoma (anaplastic large cell alk negative; one of the rarer types of non-Hodgkin's lyLymphoma (anaplastic large cell alk negative; one of the rarer types of non-Hodgkin's lymphomalymphoma).

Diagnosing lymphoma requires finding cancerous cells on microscopic examination.

As of 3/22/10, NCSU's BMT Unit has performed the procedure on 14 dogs with B - cell Lymphoma.

Additionally, Dr Breen discussed a new drug, Tinovia, which appears to work on resistant lymphoma with a new technology that allows it to soak into diseased cells, with one potential serious side effect of lung fibrosis, especially in Westies.

She found expanded CD8 T cells and defined the clonality on T cell assays to help differentiate elevated lymphocytes due to E canis infection compared to lymphoma or leukemia.

Some of her work has included ground - breaking studies on T - cell transplants for dogs with lymphoma and genetic modification of these cells for treating canine bone cancer.

Although he has a history of T - Cell Lymphoma manifesting as a tumor on a loop of small intestine, the -LSB-...]

This award supports our on - going work developing genetically re-directed T cells to provide complete and durable remission in dogs with B cell lymphoma.»

This determination is based on how rapidly the cancer cells appear to be dividing and how malignant the cells appear to be; high - grade lymphoma is fast - growing and more malignant.

Lectures provided on Mast cell tumors, Updates in Canine Lymphoma, Novel Therapies, Oral tumors and Soft tissue sarcoma.

SECTION 2: SELECTED TOPICS ON CLINICAL PATHOLOGY Adenocarcinoma Behavioral Problems Canine Hip Dysplasia Ear Infections (Otitis) Epilepsy Fibrosarcoma Gastric Dilation - Volvulus (GDV) or Bloat Hemangiosarcoma Hypothyrodism Lymphoma Malignant Histiocytosis Mast Cell Tumors Melanoma Nonmalignant Tumors of the Skin and Soft Tissues Osteochondrosis Osteosarcoma Patellar Luxation

Lectures provided on: Canine and Feline Lymphoma, What's new in Oncology, How to read a histopathology report; Canine mast cell tumours and TKIs; Canine Hemangiosarcoma.

Canine Cutaneous lymphoma is a cancer of the white blood cells with lumps on the skin as the canine skin cancer symptoms.